Browsing by Author "Roa Strauch, Juan Carlos Enrique"
Now showing 1 - 20 of 94
Results Per Page
Sort Options
- ItemAdvances towards the use of gastrointestinal tumor patient-derived organoids as a therapeutic decision-making tool(2023) Obreque Castro, Javiera Constanza; Vergara Gómez, Luis; Venegas Labra, Nicolás; Weber, Helga; Owen, Gareth Ivor; Pérez Moreno, Pablo; Leal, Pamela; Roa Strauch, Juan Carlos Enrique; Bizama, CarolinaIn December 2022 the US Food and Drug Administration (FDA) removed the requirement that drugs in development must undergo animal testing before clinical evaluation, a declaration that now demands the establishment and verification of ex vivo preclinical models that closely represent tumor complexity and that can predict therapeutic response. Fortunately, the emergence of patient-derived organoid (PDOs) culture has enabled the ex vivo mimicking of the pathophysiology of human tumors with the reassembly of tissue-specific features. These features include histopathological variability, molecular expression profiles, genetic and cellular heterogeneity of parental tissue, and furthermore growing evidence suggests the ability to predict patient therapeutic response. Concentrating on the highly lethal and heterogeneous gastrointestinal (GI) tumors, herein we present the state-of-the-art and the current methodology of PDOs. We highlight the potential additions, improvements and testing required to allow the ex vivo of study the tumor microenvironment, as well as offering commentary on the predictive value of clinical response to treatments such as chemotherapy and immunotherapy.
- ItemAKT/mTOR substrate p70S6k is frequently phosphorylated in gallbladder cancer tissue and cell lines(2013) Leal, Pamela; García Cañete, Patricia; Sandoval, Alejandra; Buchegger, Kurt; Weber, Helga; Tapia, Oscar; Roa Strauch, Juan Carlos Enrique
- ItemAngiotensin-(1-9) prevents cardiomyocyte hypertrophy by controlling mitochondrial dynamics via miR-129-3p/PKIA pathway(2020) Sotomayor-Flores, C.; Rivera-Mejias, P.; Vasquez-Trincado, C.; Lopez-Crisosto, C.; Morales, P. E.; Pennanen, C.; Polakovicova, Iva; Roa Strauch, Juan Carlos Enrique; Ocaranza, María Paz; Corvalán R., Alejandro; Aliaga-Tobar, V.; Garcia, L.; Rothermel, B. A.; Maracaja-Coutinho, V.; Ho-Xuan, H.; Meister, G.; Chiong, M.; Parra, V.; Lavandero, S.
- ItemAssociation of inflammatory and other immune markers with gallbladder cancer : Results from two independent case-control studies(2016) Pinto, L.; Koshiol, J.; Castro, F.; Kemp, T.; Gao, Y.; Roa Strauch, Juan Carlos Enrique; Wang, B.; Nogueira, L.; Araya, J.; Ferreccio Readi, Catterina; Rashid, A.; Hsing, A.; Hildesheim, A.; Shen, M.; Pfeiffer, R.
- ItemBeneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis(2015) Pizarro, M.; Solís, Nancy; Quintero, P.; Barrera Martínez, Francisco José; Cabrera, D.; Rojas-de Santiago, P.; Arab Verdugo, Juan Pablo; Padilla, O.; Roa Strauch, Juan Carlos Enrique; Moshage, H.; Wree, A.; Inzaugarat, E.; Feldstein, A.; Fardella B., Carlos; Baudrand Biggs, René; Riquelme, A.; Arrese Jiménez, Marco
- ItemCalcium calmodulin dependent kinase kinase 2-a novel therapeutic target for gastric adenocarcinoma(2015) Subbannayya, Yashwanth; Syed, Nazia; Barbhuiya, Mustafa A.; Roa Strauch, Juan Carlos Enrique; Marimuthu, Arivusudar; Sahasrabuddhe, Nandini; Pinto, Sneha M.; Manda, Srikanth Srinivas; Renuse, Santosh; Manju, HC; Zameer, Mohammed Abdul Lateef; Sharma, Jyoti; Brait, Mariana; Srikumar, Kotteazeth; Raja, Remya; Vijaya Kumar, M.; Kumar, KV Veerendra; Prasad, TS Keshava; Ramaswamy, Girija; Kumar, Rekha Vijay; Pandey, Akhilesh; Gowda, Harsha; Chatterjee, Aditi
- ItemCanonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth(2020) Chervo, M. F.; Russo, R. I. C.; Petrillo, E.; Izzo, F.; De Martino, M.; Bellora, N.; Cenciarini, M. E.; Chiauzzi, V. A.; de la Parra, L. S.; Roa Strauch, Juan Carlos Enrique; Pereyra, M. G.; Guttlein, L. N.; Podhajcer, O. L.; Daniotti, J. L.; Dupont, A.; Barchuk, S.; Figurelli, S.; Della Vecchia, D. L.; Guzman, P.; Proietti, C. J.; Schillaci, R.; Elizalde, P. V.
- ItemCarcinogenic Helicobacter pylori Strains Selectively Dysregulate the In Vivo Gastric Proteome, Which May Be Associated with Stomach Cancer Progression(2019) Noto, Jennifer M.; Rose, Kristie L.; Hachey, Amanda J.; Delgado, Alberto G.; Romero Gallo, Judith; Wroblewski, Lydia E.; Schneider, Barbara G.; Shah, Shailja C.; Cover, Timothy L.; Roa Strauch, Juan Carlos Enrique; Wilson, Keith T.; Israel, Dawn A.; et. Al.
- ItemCellular FLICE-like Inhibitory Protein Long Form (c-FLIPL) Overexpression is Related to Cervical Cancer Progression(2013) Ili, Carmen Gloria; Brebi, Priscilla; Tapia, Oscar; Sandoval, Alejandra; López, Jaime; García Muñoz, Patricia; Leal, Pamela; Sidransky, David; Guerrero Preston, Rafael; Roa Strauch, Juan Carlos Enrique
- ItemCirculating MicroRNAs as Biomarkers in Biliary Tract Cancers(2016) Letelier, P.; Riquelme, I.; Hernández, A.; Guzmán, N.; Farías, J.; Roa Strauch, Juan Carlos Enrique
- ItemComplete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumor(2014) Quezada Sanhueza, Nicolás; Acevedo Claros, Francisco Nicolás; Marambio, A.; León, F.; Galindo A., Héctor; Roa Strauch, Juan Carlos Enrique; Jarufe Cassis, NicolásINTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.
- ItemConnective Tissue Growth Factor Immunohistochemical Expression Is Associated With Gallbladder Cancer Progression(2013) García Cañete, Patricia; Leal, Pamela; Álvarez, Héctor; Brebi, Priscilla; Ili, Carmen Gloria; Tapia, Oscar; Roa Strauch, Juan Carlos Enrique
- ItemCorrection to : MicroRNA‑335‑5p is a potential suppressor of metastasis and invasion in gastric cancer(2021) Sandoval Bórquez, Alejandra; Polakovicova, Iva; Carrasco Véliz, Nicolás; Lobos González, Lorena; Riquelme, Ismael; Carrasco Avino, Gonzalo; Bizama, Carolina; Norero Muñoz, Enrique; Owen, Gareth Ivor; Roa Strauch, Juan Carlos Enrique; Corvalán R., AlejandroAn amendment to this paper has been published and can be accessed via the original article.
- ItemDiagnóstico de la infección por virus papiloma humano en el hombre(2013) Silva, Ramón; León, Daniela; Brebi, Priscilla; Lli, Carmen Gloria; Roa Strauch, Juan Carlos Enrique; Sánchez, Raúl
- ItemDifferential expression profile of CXCR3 splicing variants is associated with thyroid neoplasia. Potential role in papillary thyroid carcinoma oncogenesis?(2018) Urra, Soledad; Fischer, Martin C.; Martinez, Jose R.; Veliz, Loreto; Orellana, Paulina; Solar González, Antonieta Alejandra; Bohmwald Prieto, Karen; Kalergis Parra, Alexis Mikes; Riedel, Claudia; Corvalán R., Alejandro; Roa Strauch, Juan Carlos Enrique; Fuentealba, Rodrigo; Cáceres, C. Joaquín; López Lastra, Marcelo Andrés; León Ramírez, Augusto; Droppelmann, Nicolás; Gonzalez, Hernan E.
- ItemDisección submucosa endoscópica en cáncer gástrico incipiente : experiencia inicial en el Hospital Clínico de la Pontificia Universidad Católica de Chile(2015) Donoso D., Andrés; Sharp Pittet, Allan Carlos; Parra Blanco, Adolfo; Roa Strauch, Juan Carlos Enrique; Bachler, Jean Phillipe; Crovari Eulufi, Fernando; Funke, Ricardo; Pimentel Muller, Fernando; Ibáñez Anrique, Luis; Guzmán Karadima, Sergio; Donoso D., Andrés; Sharp P. Allan; Parra Blanco, Adolfo; Roa Strauch, Juan Carlos Enrique; Bachler, Jean Phillipe; Crovari Eulufi, Fernando; Funke, Ricardo; Pimentel Muller, Fernando; Ibáñez Anrique, Luis; Guzman, Sergio
- ItemEarly gallbladder carcinoma has a favorable outcome but Rokitansky-Aschoff sinus involvement is an adverse prognostic factor(2013) Roa Strauch, Juan Carlos Enrique; Tapia,Oscar; Manterola, Carlos; Villaseca, Miguel; Guzmán, Pablo; Araya, Juan Carlos; Bagci, Pelin; Saka, Burcu; Adsay, Volkan
- ItemEffects of c-FLIPL Knockdown in Cervical Uterine Carcinoma Cell Lines(2015) Ili, Caremen G.; Brebi, Priscilla; García Cañete, Patricia; Leal, Pamela; Lopez, Jaime; Tapia, Oscar; Letelier, Pablo; Weber, Helga; Castillo, Jonathan; Roa Strauch, Juan Carlos Enrique
- ItemEmerging Role of miRNAs in the Drug Resistance of Gastric Cancer(2016) Riquelme, I.; Letelier, P.; Riffo, A.; Brebi, P.; Roa Strauch, Juan Carlos Enrique
- ItemEpidemiología del cáncer de tiroides en Chile. Resultados del estudio INCATIR(2014) Sapunar, J.; Muñoz, S.; Roa Strauch, Juan Carlos Enrique